Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
Add more filters










Publication year range
1.
Stem Cell Res Ther ; 12(1): 304, 2021 05 29.
Article in English | MEDLINE | ID: mdl-34051850

ABSTRACT

BACKGROUND: Graves' ophthalmopathy (GO) is a disorder, in which orbital connective tissues get in inflammation and increase in volume. Stimulants such as thyroid-stimulating hormone (TSH), insulin-like growth factor 1(IGF-1), IL-1, interferon γ, and platelet-derived growth factor cause differentiation into adipocytes of orbital fibroblasts (OFs) in the orbital fat and extraocular muscles. Human placental mesenchymal stem cells (hPMSCs) are known to have immune modulation effects on disease pathogenesis. Some reports suggest that hPMSCs can elicit therapeutic effects, but to date, research on this has been insufficient. In this study, we constructed PRL-1 overexpressed hPMSCs (hPMSCsPRL-1) in an attempt to enhance the suppressive function of adipogenesis in GO animal models. METHODS: In order to investigate the anti-adipogenic effects, primary OFs were incubated with differentiation medium for 10 days. After co-culturing with hPMSCsPRL-1, the characteristics of the OFs were analyzed using Nile red stain and quantitative real-time polymerase chain reaction. We then examined the in vivo regulatory effectiveness of hPMSCsPRL-1 in a GO mouse model that immunized by leg muscle electroporation of pTriEx1.1Neo-hTSHR A-subunit plasmid. Human PMSCsPRL-1 injection was performed in left orbit. We also analyzed the anti-adipogenic effects of hPMSCsPRL-1 in the GO model. RESULTS: We found that hPMSCsPRL-1 inhibited adipogenic activation factors, specifically PPARγ, C/EBPα, FABP4, SREBP2, and HMGCR, by 75.1%, 50%, 79.6%, 81.8%, and 87%, respectively, compared with naïve hPMSCs in adipogenesis-induced primary OFs from GO. Moreover, hPMSCsPRL-1 more effectively inhibited adipogenic factors ADIPONECTIN and HMGCR by 53.2% and 31.7%, respectively, than hPMSCs, compared with 15.8% and 29.8% using steroids in the orbital fat of the GO animal model. CONCLUSION: Our findings suggest that hPMSCsPRL-1 would restore inflammation and adipogenesis of GO model and demonstrate that they could be applied as a novel treatment for GO patients.


Subject(s)
Graves Ophthalmopathy , Mesenchymal Stem Cells , Adipogenesis , Animals , Cells, Cultured , Female , Fibroblasts , Graves Ophthalmopathy/therapy , Humans , Hydroxymethylglutaryl CoA Reductases , Orbit , Placenta , Pregnancy
2.
J Korean Med Sci ; 35(36): e305, 2020 Sep 14.
Article in English | MEDLINE | ID: mdl-32924342

ABSTRACT

BACKGROUND: Oxidative stress induced by chronic hyperglycemia is recognized as a significant mechanistic contributor to the development of diabetic kidney disease (DKD). Nonphagocytic nicotinamide adenine dinucleotide phosphate oxidase 4 (Nox4) is a major source of reactive oxygen species (ROS) in many cell types and in the kidney tissue of diabetic animals. We designed this study to explore the therapeutic potential of chloroquine (CQ) and amodiaquine (AQ) for inhibiting mitochondrial Nox4 and diabetic tubular injury. METHODS: Human renal proximal tubular epithelial cells (hRPTCs) were cultured in high-glucose media (30 mM D-glucose), and diabetes was induced with streptozotocin (STZ, 50 mg/kg i.p. for 5 days) in male C57BL/6J mice. CQ and AQ were administered to the mice via intraperitoneal injection for 14 weeks. RESULTS: CQ and AQ inhibited mitochondrial Nox4 and increased mitochondrial mass in hRPTCs under high-glucose conditions. Reduced mitochondrial ROS production after treatment with the drugs resulted in decreased endoplasmic reticulum (ER) stress, suppressed inflammatory protein expression and reduced cell apoptosis in hRPTCs under high-glucose conditions. Notably, CQ and AQ treatment diminished Nox4 activation and ER stress in the kidneys of STZ-induced diabetic mice. In addition, we observed attenuated inflammatory protein expression and albuminuria in STZ-induced diabetic mice after CQ and AQ treatment. CONCLUSION: We substantiated the protective actions of CQ and AQ in diabetic tubulopathy associated with reduced mitochondrial Nox4 activation and ER stress alleviation. Further studies exploring the roles of mitochondrial Nox4 in the pathogenesis of DKD could suggest new therapeutic targets for patients with DKD.


Subject(s)
Amodiaquine/pharmacology , Chloroquine/pharmacology , Endoplasmic Reticulum Stress/drug effects , Mitochondria/metabolism , NADPH Oxidase 4/metabolism , Amodiaquine/chemistry , Amodiaquine/metabolism , Amodiaquine/therapeutic use , Animals , Apoptosis/drug effects , Cells, Cultured , Chloroquine/chemistry , Chloroquine/metabolism , Chloroquine/therapeutic use , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/pathology , Diabetes Mellitus, Type 1/pathology , Glucose/pharmacology , Humans , Kidney Tubules, Proximal/cytology , Kidney Tubules, Proximal/metabolism , Male , Mice , Mice, Inbred C57BL , NADPH Oxidase 4/antagonists & inhibitors , Reactive Oxygen Species/metabolism
3.
Am J Physiol Renal Physiol ; 317(4): F767-F780, 2019 10 01.
Article in English | MEDLINE | ID: mdl-31390268

ABSTRACT

We examined the effects of empagliflozin, a selective inhibitor of Na+-glucose cotransporter 2, on mitochondrial quality control and autophagy in renal tubular cells in a diabetic environment in vivo and in vitro. Human renal proximal tubular cells (hRPTCs) were incubated under high-glucose conditions. Diabetes was induced with streptozotocin in male C57BL/6J mice. Improvements in mitochondrial biogenesis and balanced fusion-fission protein expression were noted in hRPTCs after treatment with empagliflozin in high-glucose media. Empagliflozin also increased autophagic activities in renal tubular cells in the high-glucose environment, which was accompanied with mammalian target of rapamycin inhibition. Moreover, reduced mitochondrial reactive oxygen species production and decreased apoptotic and fibrotic protein expression were observed in hRPTCs after treatment with empagliflozin, even in the hyperglycemic circumstance. Importantly, empagliflozin restored AMP-activated protein kinase-α phosphorylation and normalized levels of AMP-to-ATP ratios in hRPTCs subjected to a high-glucose environment, which suggests the way that empagliflozin is involved in mitochondrial quality control. Empagliflozin effectively suppressed Na+-glucose cotransporter 2 expression and ameliorated renal morphological changes in the kidneys of streptozotocin-induced diabetic mice. Electron microscopy analysis showed that mitochondrial fragmentation was decreased and 8-hydroxy-2'-deoxyguanosine content was low in renal tubular cells of empagliflozin treatment groups compared with those of the diabetic control group. We suggest one mechanism related to the renoprotective actions of empagliflozin, which reverse mitochondrial dynamics and autophagy.


Subject(s)
Autophagy/drug effects , Benzhydryl Compounds/therapeutic use , Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/pathology , Glucosides/therapeutic use , Mitochondria/drug effects , Mitochondria/pathology , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Adenosine Monophosphate/metabolism , Adenosine Triphosphate/metabolism , Animals , Apoptosis Regulatory Proteins/antagonists & inhibitors , Cell Line , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/genetics , Diabetes Mellitus, Experimental/pathology , Gene Expression/drug effects , Humans , Kidney Tubules, Proximal/drug effects , Kidney Tubules, Proximal/pathology , Male , Mice , Mice, Inbred C57BL , Organelle Biogenesis , Reactive Oxygen Species/metabolism , Sodium-Glucose Transporter 2/metabolism
4.
Biomed Res Int ; 2018: 3421568, 2018.
Article in English | MEDLINE | ID: mdl-30225249

ABSTRACT

Thymosin ß4 (Tß4) treatment was known to show the potential therapeutic effects on diabetic complications. This study was performed to determine if Tß4 expression is changed in both serum and tissues under diabetic conditions and can be a serum biomarker. Type 1 diabetic mice were induced in C57/BL6J mice by intraperitoneal injection of streptozotocin (STZ) at a dose of 50 mg/kg body weight. The mice were sacrificed at 16 weeks after STZ injection. Tissues and plasmas were obtained to determine the expression levels of Tß4 using ELISA, real time RT-PCR, and immunohistochemistry. The average serum glucose level was increased to approximately 400 mg/dL beginning 2 weeks after the five injections of STZ and lasting for at least 13 weeks until sacrifice. The plasma and tissue levels of Tß4 in the age-matched control mice were not significantly different from those of the diabetic mice. In conclusion, the Tß4 expression level in the plasmas and tissues of diabetic mice was not affected by diabetic conditions. It indirectly suggests that the therapeutic effect of Tß4 on diabetic complications is due to its regenerative effects on damaged tissue but not to the changed expression level of Tß4 in plasma and tissues of diabetes.


Subject(s)
Diabetes Mellitus, Experimental/blood , Thymosin/metabolism , Animals , Injections, Intraperitoneal , Mice , Streptozocin , Thymosin/therapeutic use
5.
Cell Transplant ; 27(5): 814-830, 2018 05.
Article in English | MEDLINE | ID: mdl-29871515

ABSTRACT

Parkinson's disease (PD) is the second most common age-related neurodegenerative disease in the elderly and the patients suffer from uncontrolled movement disorders due to loss of dopaminergic (DA) neurons on substantia nigra pars compacta (SNpc). We previously reported that transplantation of human fetal midbrain-derived neural precursor cells restored the functional deficits of a 6-hydroxy dopamine (6-OHDA)-treated rodent model of PD but its low viability and ethical issues still remain to be solved. Albeit immune privilege and neural differentiation potentials suggest mesenchymal stem cells (MSCs) from various tissues including human placenta MSCs (hpMSCs) for an alternative source, our understanding of their therapeutic mechanisms is still limited. To expand our knowledge on the MSC-mediated PD treatment, we here investigated the therapeutic mechanism of hpMSCs and hpMSC-derived neural phenotype cells (hpNPCs) using a PD rat model. Whereas both hpMSCs and hpNPCs protected DA neurons in the SNpc at comparable levels, the hpNPC transplantation into 6-OHDA treated rats exhibited longer lasting recovery in motor deficits than either the saline or the hpMSC treated rats. The injected hpNPCs induced delta-like ligand (DLL)1 and neurotrophic factors, and influenced environments prone to neuroprotection. Compared with hpMSCs, co-cultured hpNPCs more efficiently protected primary neural precursor cells from midbrain against 6-OHDA as well as induced their differentiation into DA neurons. Further experiments with conditioned media from hpNPCs revealed that the secreted factors from hpNPCs modulated immune responses and neural protection. Taken together, both DLL1-mediated contact signals and paracrine factors play critical roles in hpNPC-mediated improvement. First showing here that hpMSCs and their neural derivative hpNPCs were able to restore the PD-associated deficits via dual mechanisms, neuroprotection and immunosuppression, this study expanded our knowledge of therapeutic mechanisms in PD and other age-related diseases.


Subject(s)
Brain/pathology , Inflammation/pathology , Neural Stem Cells/cytology , Neuroprotection , Parkinson Disease/pathology , Placenta/cytology , Animals , Cell Death , Cell Differentiation , Cell Survival , Cells, Cultured , Cellular Microenvironment , Corpus Striatum/pathology , Disease Models, Animal , Dopaminergic Neurons/metabolism , Female , Humans , Immunomodulation , Intercellular Signaling Peptides and Proteins/metabolism , Mesenchymal Stem Cells/cytology , Mice , Microglia/metabolism , Motor Activity , Neural Stem Cells/transplantation , Neurturin/metabolism , Oxidopamine , Parkinson Disease/physiopathology , Pregnancy , Rats, Sprague-Dawley
6.
Sci Rep ; 8(1): 8774, 2018 06 08.
Article in English | MEDLINE | ID: mdl-29884802

ABSTRACT

We investigated the effects of chloroquine (CQ) and amodiaquine (AQ) on AMPK phosphorylation in renal tubular cells in a diabetic environment in vivo and in vitro. We also examined whether CQ- or AQ-mediated AMPK activity restoration attenuated diabetic tubulopathy by normalizing mitochondrial fragmentation. Human renal proximal epithelial cells (HKC8) were incubated in high-glucose conditions. Diabetes was induced with streptozotocin in male C57/BL6J mice. Treatment with CQ or AQ abolished high-glucose-induced phospho-AMPK and phosph-PGC1α down-regulation in HKC8 cells. Improvements in functional mitochondrial mass and balanced fusion/fission protein expression were observed in HKC8 cells after treatment with CQ or AQ in high-glucose conditions. Moreover, decreased mitochondrial ROS production and reduced apoptotic and fibrotic protein expression were noted in HKC8 cells after treatment with CQ or AQ, even in high-glucose conditions. CQ and AQ treatment effectively mitigated albuminuria and renal histopathologic changes and increased AMPK activity in the kidneys of diabetic mice. Electron microscopy analysis showed that mitochondrial fragmentation was decreased, and 8-OHdG content was low in the renal tubular cells of the CQ and AQ treatment groups compared with those of the diabetic control group. Our results suggest that CQ and AQ may be useful treatments for patients with diabetic kidney disease.


Subject(s)
AMP-Activated Protein Kinases/metabolism , Amodiaquine/therapeutic use , Chloroquine/therapeutic use , Diabetes Mellitus, Experimental/complications , Diabetic Nephropathies/drug therapy , Enzyme Activators/therapeutic use , Animals , Antimalarials/therapeutic use , Cell Line , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/pathology , Glucose/metabolism , Humans , Kidney Tubules/drug effects , Kidney Tubules/metabolism , Kidney Tubules/pathology , Male , Mice, Inbred C57BL , Mitochondria/drug effects , Mitochondria/metabolism , Mitochondria/pathology , Phosphorylation/drug effects
7.
Sci Rep ; 7(1): 16782, 2017 12 01.
Article in English | MEDLINE | ID: mdl-29196746

ABSTRACT

Diabetes is a risk factor for acute kidney injury (AKI) and chronic kidney disease (CKD). Diabetic patients are easy to progress to CKD after AKI. Currently, activation of fibrotic signalling including transforming growth factor-ß1 (TGF-ß1) is recognized as a key mechanism in CKD. Here, we investigated the influence of diabetes on CKD progression after AKI by using a unilateral renal ischaemia-reperfusion injury (IRI) model in diabetic mice. IRI induced extensive tubular injury, fibrosis and lymphocyte recruitment at 3 weeks after IRI, irrespective of diabetes. However, diabetes showed sustained tubular injury and markedly increased fibrosis and lymphocyte recruitment compared with non-diabetes at 5 week after IRI. The mRNAs and proteins related to TGF-ß1 and sonic hedgehog (Shh) signalling were significantly higher in diabetic versus non-diabetic IRI kidneys. During the in vitro study, the hyperglycaemia induced the activation of TGF-ß1 and Shh signalling and also increased profibrogenic phenotype change. However, hyperglycaemic control with insulin did not improve the progression of renal fibrosis and the activation of TGF-ß1 and Shh signalling. In conclusion, diabetes promotes CKD progression of AKI via activation of the TGF-ß1 and Shh signalling pathways, but insulin treatment was not enough for preventing the progression of renal fibrosis.


Subject(s)
Acute Kidney Injury/complications , Diabetes Mellitus, Experimental/complications , Renal Insufficiency, Chronic/etiology , Reperfusion Injury/complications , Signal Transduction , Acute Kidney Injury/genetics , Acute Kidney Injury/metabolism , Animals , Cell Line , Diabetes Mellitus, Experimental/genetics , Diabetes Mellitus, Experimental/metabolism , Disease Models, Animal , Disease Progression , Gene Expression Regulation , Hedgehog Proteins/genetics , Hedgehog Proteins/metabolism , Humans , Male , Mice , Renal Insufficiency, Chronic/genetics , Renal Insufficiency, Chronic/metabolism , Reperfusion Injury/genetics , Reperfusion Injury/metabolism , Streptozocin , Transforming Growth Factor beta1/genetics , Transforming Growth Factor beta1/metabolism
8.
J Diabetes Res ; 2017: 6483572, 2017.
Article in English | MEDLINE | ID: mdl-28409163

ABSTRACT

Purpose. In this study, we investigated the effect of PGC1α activators on mitochondrial fusion, fission, and autophagic quality control in renal tubular cells in a diabetic environment in vivo and in vitro. We also examined whether the upregulation of PGC1α attenuates diabetic tubulopathy by normalizing mitochondrial homeostasis. Methods. HKC8 cells were subjected to high-glucose conditions (30 mM D-glucose). Diabetes was induced with streptozotocin (STZ, 50 mg/kg i.p. for 5 days) in male C57/BL6J mice. AICAR or metformin was used as a PGC1α activator. Results. Treatment with the PGC1α activators AICAR and metformin improved functional mitochondrial mass in HKC8 cells in high-glucose conditions. Moreover, in renal proximal tubular cells, increased PGC1α activity correlated with the reversal of changes in Drp1, Mfn1, and LC3-II protein expression in a high-glucose environment. Normalized mitochondrial life cycles resulted in low ROS production and reduced apoptosis. AICAR and metformin treatment effectively mitigated albuminuria and renal histopathology and decreased the expression of TGFß1 and αSMA in the kidneys of diabetic mice. Conclusions. Our results demonstrate that increases in PGC1α activity improve diabetic tubulopathy by modulating mitochondrial dynamics and autophagy.


Subject(s)
Aminoimidazole Carboxamide/analogs & derivatives , Autophagy/drug effects , Diabetes Mellitus, Experimental/metabolism , Diabetic Nephropathies/metabolism , Hypoglycemic Agents/pharmacology , Kidney Tubules, Proximal/drug effects , Metformin/pharmacology , Mitochondrial Dynamics/drug effects , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/drug effects , Ribonucleotides/pharmacology , Aminoimidazole Carboxamide/pharmacology , Animals , Apoptosis/drug effects , Cell Line , Glucose/pharmacology , Humans , Kidney Tubules, Proximal/cytology , Male , Mice , Sweetening Agents/pharmacology
9.
Stem Cells Transl Med ; 6(2): 576-588, 2017 02.
Article in English | MEDLINE | ID: mdl-28191758

ABSTRACT

We have developed a good manufacturing practice for long-term cultivation of fetal human midbrain-derived neural progenitor cells. The generation of human dopaminergic neurons may serve as a tool of either restorative cell therapies or cellular models, particularly as a reference for phenotyping region-specific human neural stem cell lines such as human embryonic stem cells and human inducible pluripotent stem cells. We cultivated 3 different midbrain neural progenitor lines at 10, 12, and 14 weeks of gestation for more than a year and characterized them in great detail, as well as in comparison with Lund mesencephalic cells. The whole cultivation process of tissue preparation, cultivation, and cryopreservation was developed using strict serum-free conditions and standardized operating protocols under clean-room conditions. Long-term-cultivated midbrain-derived neural progenitor cells retained stemness, midbrain fate specificity, and floorplate markers. The potential to differentiate into authentic A9-specific dopaminergic neurons was markedly elevated after prolonged expansion, resulting in large quantities of functional dopaminergic neurons without genetic modification. In restorative cell therapeutic approaches, midbrain-derived neural progenitor cells reversed impaired motor function in rodents, survived well, and did not exhibit tumor formation in immunodeficient nude mice in the short or long term (8 and 30 weeks, respectively). We conclude that midbrain-derived neural progenitor cells are a promising source for human dopaminergic neurons and suitable for long-term expansion under good manufacturing practice, thus opening the avenue for restorative clinical applications or robust cellular models such as high-content or high-throughput screening. Stem Cells Translational Medicine 2017;6:576-588.


Subject(s)
Cell Proliferation , Dopaminergic Neurons/physiology , Mesencephalon/embryology , Neural Stem Cells/physiology , Neurogenesis , Parkinsonian Disorders/surgery , Stem Cell Transplantation/methods , Animals , Biomarkers/metabolism , Cell Culture Techniques , Cell Line , Disease Models, Animal , Dopaminergic Neurons/metabolism , Female , Gestational Age , Humans , Male , Mice, Inbred BALB C , Mice, Nude , Motor Activity , Neural Stem Cells/metabolism , Oxidopamine , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/pathology , Parkinsonian Disorders/physiopathology , Phenotype , Rats, Sprague-Dawley , Recovery of Function , Risk Assessment , Stem Cell Transplantation/adverse effects , Teratoma/etiology , Teratoma/pathology , Time Factors
10.
Asian-Australas J Anim Sci ; 29(9): 1353-62, 2016 Sep.
Article in English | MEDLINE | ID: mdl-26954201

ABSTRACT

Hanwoo, a Korean native cattle (Bos taurus coreana), has great economic value due to high meat quality. Also, the breed has genetic variations that are associated with production traits such as health, disease resistance, reproduction, growth as well as carcass quality. In this study, next generation sequencing technologies and the availability of an appropriate reference genome were applied to discover a large amount of single nucleotide polymorphisms (SNPs) in ten Hanwoo bulls. Analysis of whole-genome resequencing generated a total of 26.5 Gb data, of which 594,716,859 and 592,990,750 reads covered 98.73% and 93.79% of the bovine reference genomes of UMD 3.1 and Btau 4.6.1, respectively. In total, 2,473,884 and 2,402,997 putative SNPs were discovered, of which 1,095,922 (44.3%) and 982,674 (40.9%) novel SNPs were discovered against UMD3.1 and Btau 4.6.1, respectively. Among the SNPs, the 46,301 (UMD 3.1) and 28,613 SNPs (Btau 4.6.1) that were identified as Hanwoo-specific SNPs were included in the functional genes that may be involved in the mechanisms of milk production, tenderness, juiciness, marbling of Hanwoo beef and yellow hair. Most of the Hanwoo-specific SNPs were identified in the promoter region, suggesting that the SNPs influence differential expression of the regulated genes relative to the relevant traits. In particular, the non-synonymous (ns) SNPs found in CORIN, which is a negative regulator of Agouti, might be a causal variant to determine yellow hair of Hanwoo. Our results will provide abundant genetic sources of variation to characterize Hanwoo genetics and for subsequent breeding.

11.
Asian-Australas J Anim Sci ; 28(11): 1537-44, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26580276

ABSTRACT

Meat and carcass quality attributes are of crucial importance influencing consumer preference and profitability in the pork industry. A set of 400 Berkshire pigs were collected from Dasan breeding farm, Namwon, Chonbuk province, Korea that were born between 2012 and 2013. To perform genome wide association studies (GWAS), eleven meat and carcass quality traits were considered, including carcass weight, backfat thickness, pH value after 24 hours (pH24), Commission Internationale de l'Eclairage lightness in meat color (CIE L), redness in meat color (CIE a), yellowness in meat color (CIE b), filtering, drip loss, heat loss, shear force and marbling score. All of the 400 animals were genotyped with the Porcine 62K SNP BeadChips (Illumina Inc., USA). A SAS general linear model procedure (SAS version 9.2) was used to pre-adjust the animal phenotypes before GWAS with sire and sex effects as fixed effects and slaughter age as a covariate. After fitting the fixed and covariate factors in the model, the residuals of the phenotype regressed on additive effects of each single nucleotide polymorphism (SNP) under a linear regression model (PLINK version 1.07). The significant SNPs after permutation testing at a chromosome-wise level were subjected to stepwise regression analysis to determine the best set of SNP markers. A total of 55 significant (p<0.05) SNPs or quantitative trait loci (QTL) were detected on various chromosomes. The QTLs explained from 5.06% to 8.28% of the total phenotypic variation of the traits. Some QTLs with pleiotropic effect were also identified. A pair of significant QTL for pH24 was also found to affect both CIE L and drip loss percentage. The significant QTL after characterization of the functional candidate genes on the QTL or around the QTL region may be effectively and efficiently used in marker assisted selection to achieve enhanced genetic improvement of the trait considered.

12.
Cell Transplant ; 22(7): 1263-79, 2013.
Article in English | MEDLINE | ID: mdl-23031199

ABSTRACT

Stem cell-based cell replacement of lost midbrain dopamine (mDA) neurons is a potential therapy for Parkinson's disease (PD). Toward this goal, it is critical to optimize various aspects of cell transplantation and to assess functional recovery through behavioral tests in validated animal model(s) of PD. At present, cell transplantation studies are being done almost exclusively in neurotoxin-based animal models, because few genetic models of PD exhibit robust mDA neuronal loss. Here we used a genetic model of PD, the aphakia mouse, which demonstrates selective degeneration of mDA neurons in the substantia nigra. We systematically investigated the functional effects of transplanting embryonic stem cell-derived cells at different stages of in vitro differentiation: embryoid body (EB), neural progenitor (NP), and neuronal differentiated (ND) stages. We found that transplantation of NP cells yielded the best outcomes for both survival and behavioral improvement, while transplantation of EB and ND cells resulted in high teratoma-like tumor formation and poor survival, respectively. In behavioral paradigms specific to basal ganglia, the NP cells group prominently improved motor behavioral defects 1 and 2 months posttransplantation. Furthermore, we found that NP cell transplantation also improved cognitive impairments of aphakia mice, as examined by the passive avoidance task. Importantly, these graft-induced functional improvements well correlated with survival of tyrosine hydroxylase-positive DA neurons. Taken together, we propose that the aphakia mouse can serve as a novel and useful platform for cell transplantation studies to assess both neurological and cognitive improvements and that NP stage cells represent an optimal stage for transplantation.


Subject(s)
Cognition/physiology , Models, Genetic , Motor Activity/physiology , Neural Stem Cells/transplantation , Parkinson Disease/therapy , Animals , Aphakia/pathology , Cell Differentiation , Disease Models, Animal , Dopamine/metabolism , Dopaminergic Neurons/enzymology , Embryonic Stem Cells/cytology , Mesencephalon/pathology , Mice , Neural Stem Cells/cytology , Parkinson Disease/genetics , Teratoma/pathology , Tyrosine 3-Monooxygenase/metabolism
13.
Eur J Med Chem ; 44(8): 3166-74, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19375195

ABSTRACT

A convenient synthesis and the biological properties of new amides, esters and other derivatives of trans-stilbene are described. The key synthetic strategies involve the Wittig-Horner reaction of a phosphonium salt 9 and an aldehyde 10 to generate (E)- or (Z)-olefins and a coupling reaction of an acid 12 and various amines 13a-n to give trans-stilbene derivatives 15a-n in high yields. A amide derivative 15g showed three times more in vitro free radical-scavenging activity than resveratrol, while another 15d exhibited strong inhibitory activity against lipopolysaccharide (LPS)(a)-induced NO generation. Allylamide analogue 15a showed the most potent neuroprotective activity in glutamate-induced primary cortical neuron cells.


Subject(s)
Drug Design , Free Radical Scavengers/chemical synthesis , Free Radical Scavengers/pharmacology , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/pharmacology , Stilbenes/chemical synthesis , Stilbenes/pharmacology , Animals , Cell Line , Cerebral Cortex/cytology , Free Radical Scavengers/chemistry , Kinetics , L-Lactate Dehydrogenase/metabolism , Mice , Mice, Inbred ICR , Microglia/cytology , Microglia/drug effects , Microglia/metabolism , Neurons/drug effects , Neurons/metabolism , Neuroprotective Agents/chemistry , Nitric Oxide/metabolism , Stereoisomerism , Stilbenes/chemistry
14.
Arch Pharm Res ; 31(9): 1098-107, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18806951

ABSTRACT

In this study, we investigated the neuroprotective effect of a benzylideneacetophenone derivative, JC3, in a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD). C57BL/6 mice were treated with MPTP (30 mg/kg, i.p.) for 5 consecutive days. JC3 (10 mg/kg, i.p.) treatment was initiated 2 h after the first administration of MPTP and then at 24-h intervals for 3 consecutive days. The mice were sacrificed for analyses 7 days after the last MPTP injection. Immunohistochemistry and Western blot were used to determine the expression levels of tyrosine hydroxylase (TH), dopamine transporter (DAT), OX-42 (a marker of microglial activation), and glial fibrillary acid protein (GFAP, a marker of astrocyte activation) in the substantia nigra (SN) and striatum (ST). The results of these experiments demonstrated that JC3 restored the decreased TH-immunoreactivity (IR) and DAT and JC3 attenuated the increase in OX-42, GFAP, and COX-2 on the SN and ST on day 7 post-MPTP injection. These results suggest that JC3 can be a neuroprotective agent in an MPTP-induced model of PD.


Subject(s)
MPTP Poisoning/prevention & control , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/pharmacology , Propiophenones/chemical synthesis , Propiophenones/pharmacology , Animals , Blotting, Western , Cyclooxygenase 2/biosynthesis , Dopamine/physiology , Dopamine Plasma Membrane Transport Proteins/biosynthesis , Glial Fibrillary Acidic Protein/biosynthesis , Immunohistochemistry , MPTP Poisoning/pathology , Mice , Neostriatum/pathology , Neurons/drug effects , Neurons/pathology , Substantia Nigra/pathology
15.
Brain Res ; 1131(1): 211-9, 2007 Feb 02.
Article in English | MEDLINE | ID: mdl-17173870

ABSTRACT

Using a mouse model of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD), this study investigated on the neuroprotective effects of acupuncture by examining whether acupuncture contributed to inhibiting microglial activation and inflammatory events. C57BL/6 mice were treated with MPTP (30 mg/kg, i.p.) for 5 consecutive days. Acupuncture was then applied to acupoints Yanglingquan (GB34) and Taichong (LR3) starting 2 h after the first MPTP administration and then at 48 h intervals until the mice were sacrificed for analyses at 1, 3, and 7 days after the last MPTP injection. These experiments demonstrated that acupuncture inhibited the decreased of the tyrosine hydroxylase (TH) immunoreactivity (IR) and generated a neuroprotective effects in the striatum (ST) and the substantia nigra (SN) on days 1, 3, and 7 post-MPTP injections. Acupuncture attenuated the increase of macrophage antigen complex-1 (MAC-1), a marker of microglial activation, at 1 and 3 days and reduced the increases in cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) expression on days 1, 3, and 7. In MPTP group, striatal dopamine (DA) was measured by 46% at 7 days, whereas DA in the acupuncture group was 78%. On the basis of these results, we suggest that acupuncture could be used as a neuroprotective intervention for the purpose of inhibiting microglial activation and inflammatory events in PD.


Subject(s)
Acupuncture/methods , Cytoprotection/physiology , Encephalitis/therapy , Gliosis/therapy , Microglia/physiology , Parkinsonian Disorders/therapy , Acupuncture/trends , Animals , Biomarkers/metabolism , Corpus Striatum/metabolism , Corpus Striatum/physiopathology , Cyclooxygenase 2/metabolism , Disease Models, Animal , Dopamine/biosynthesis , Encephalitis/chemically induced , Encephalitis/prevention & control , Gliosis/chemically induced , Gliosis/prevention & control , Macrophage-1 Antigen/metabolism , Male , Mice , Mice, Inbred C57BL , Microglia/drug effects , Nitric Oxide Synthase Type II/metabolism , Parkinsonian Disorders/physiopathology , Parkinsonian Disorders/prevention & control , Substantia Nigra/metabolism , Substantia Nigra/physiopathology , Treatment Outcome , Tyrosine 3-Monooxygenase/metabolism , Up-Regulation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL